Under the agreement, CARMAT will use the Carpentier-Edwards’ biological heart valves in its artificial heart development.
Carpentier-Edwards biological heart valves, developed by CARMAT co-founder and CSO professor Alain Carpentier, will be used in an artificial heart.
CARMAT CEO Marcello Conviti said that this partnership with Edwards Lifesciences will enable them to secure a major milestone of total artificial heart with a view to provide a solution for patients suffering from end-stage heart failure.
